共查询到18条相似文献,搜索用时 234 毫秒
1.
2.
目的:探讨p57^kip2蛋白、p16蛋白在人脑胶质瘤组织中的表达及其临床意义。方法:采用免疫组织化学SP法检测p57^kip2、p16在55例人脑胶质瘤和10例正常脑组织中的表达。结果:在55例胶质瘤组织中,p57^kip2蛋白阳性率为38.2%(21/55),显著低于正常脑组织80.0%(8/10),P=0.014。p57^kip2蛋白表达在低度恶性(Ⅰ~Ⅱ级)组显著高于高度恶性(Ⅲ~Ⅳ级)纽,P=0.029;生存时间≥2年组显著高于〈2年组,P=0.082。脑胶质瘤组织中p16蛋白表达阳性率为SO.9%(28/SS),与正常脑组织相比差异无统计学意义,P=0.051。p16蛋白表达在高度恶性(Ⅲ~Ⅳ级)组显著高于低度恶性(Ⅰ~Ⅱ级)组(P=0.022),生存时间〈2年组显著低于≥2年组,P=0.040。p57^kip2蛋白的表达与p16蛋白的表达存在正相关,rs=0.888,P=0.003。结论:p57^kip2蛋白和p16蛋白在脑胶质瘤中存在异常表达,p57^kip2蛋白和p16蛋白的表达程度与脑胶质瘤的分化程度和预后相关。 相似文献
3.
ING4及SKP2在不同级别脑胶质瘤组织中的表达 总被引:1,自引:0,他引:1
[目的]研究抑癌基因ING4及癌基因SKP2在正常脑组织及不同级别胶质瘤组织中的表达.以及其表达水平与脑胶质瘤生物学特征的关系。[方法]采用免疫组织化学技术检测70例手术切除的不同级别胶质瘤组织人及正常脑组织中ING4及SKP2的表达情况。[结果]ING4主要表达于细胞核和/或浆,正常脑组织中ING4的表达明显高于低级别与高级别胶质瘤,差异显著(t=11.8及22.5,P〈0.05);低级别胶质瘤组织中ING4的表达明显高于高级别胶质瘤,差异显著(t=-17.9,P〈0.05)。SKP2主要表达于细胞核,部分为胞浆,正常脑组织中SKP2的表达明显低于低级别与高级别胶质瘤,差异显著(t=13.7及29.5,P〈0.05);低级别胶质瘤组织中SKP2的表达明显低于高级别胶质瘤,差异显著(t=16.5,P〈0.05)。[结论]ING4基因在胶质瘤组织中表达明显下调,且ING4表达下调与胶质瘤的分级有密切关系;SKP2基因在胶质瘤组织中表达显著上调,且SKP2表达上调与胶质瘤的分级有密切关系。 相似文献
4.
目的:探讨MGMT的表达水平与脑胶质瘤的关系。方法:53例脑胶质瘤标本分为4组,经免疫组化染色后,观察MGMT的表达部位和程度。结果:MGMT在脑胶质瘤中的表达呈棕黄色或棕褐色粗大颗粒,定位于胞浆内,阳性细胞散在或局灶性,染色强度及分布不均、缺乏明显规律。不同病理分级脑胶质瘤的MGMT阳性表达率无显著性差异(P=0.335);MGMT表达阳性与MGMT表达阴性的脑胶质瘤患者的平均年龄组间无显著性差异(P=0.457);男性与女性脑胶质瘤患者的MGMT阳性表达率之问无显著性差异(P=0.519)。结论:MGMT的表达水平与脑胶质瘤的恶性度、患者的年龄及性别无明显相关性,仅根据肿瘤恶性度而使用烷化剂进行化疗是不科学的,测定MGMT在脑胶质瘤中的表达水平有助于评估人脑胶质瘤细胞对烷化剂的耐药程度。 相似文献
5.
目的:研究胶质瘤中蛋白激酶P13K、AKT2 mRNA表达与NDRG2 mRNA表达的相关性,寻找与NDRG2相互作用的上下游分子。方法:用实时定量PCR技术检测29例脑胶质瘤及相应瘤旁组织中P13K、AKT2和NDRG2 mRNA表达量。结果:29例脑胶质瘤NDRG2 mRNA表达明显低于瘤旁组织(P〈0.05),且不同病理分级间表达有显著性差异(P〈0.05),其中Ⅳ级NDRG2 mRNA表达量明显低于Ⅱ级和Ⅲ级胶质瘤(P=0.007,P=0.03);AKT2,P13K mRNA表达在胶质瘤及瘤旁组织之间无明显差异(P〉0.05)。AKT2,P13K mRNA表达与NDRG2 mRNA表达的相关性无统计学意义(P〉0.05)。结论:NDRG2可能与胶质瘤的发生发展及恶性演变有关,在mRNA表达水平,还不能认为P13K、AKT2与NDRG2之间有相关性。 相似文献
6.
着丝粒蛋白F在脑胶质瘤中的表达及其意义 总被引:3,自引:0,他引:3
目的:检测着丝粒蛋白F(CENP—F)在脑胶质瘤中的表达,探讨其临床意义。方法:采用免疫组化方法检测64例脑胶质瘤和10例正常脑组织石蜡包埋标本中CENP—F的表达。结果:CENP—F在64例脑胶质瘤中表达阳性率为76.6%.在10例正常脑组织中仅30.0%,差异有统计学意义(P〈0.01)。CENP—F的表达在不同性别、年龄、肿瘤部位、肿瘤直径、瘤周水肿及病理分类中差异无统计学意义(P〉0.05),在不同病理分级中差异有统计学意义(P〈0.05),高分级组较低分级组表达高。结论:CENP—F在脑胶质瘤中高表达,与肿瘤病理分级有关,对判断脑胶质瘤生物学特性有一定意义。 相似文献
7.
背景与目的:血管生成与肿瘤的生物学行为密切相关,本研究探讨胶质瘤促血管生存素2(angiopoietin2,Ang2)表达与血管生成的关系。方法:采用RT-PCR检测52例人脑胶质瘤和8例正常脑组织中Ang2基因表达;CD34单克隆抗体组织化学染色显示微血管,用微血管计数micro-vessel-counting,MVC)测定肿瘤血管生成。结果:50例脑胶质瘤和8例正常脑组织均可表达Ang2 mRNA片段。Ang2 mRNA表达与脑胶质瘤的血管生成呈显著正相关(r=0.821,P〈0.01);高度恶性胶质瘤Ang2 mRNA表达、MVC分别显著高于低度恶性胶质瘤(P〈0.01);低度恶性胶质瘤Ang2 mRNA表达、MVC均显著高于正常脑组织(P〈0.05)。结论:Ang2可能通过参与胶质瘤血管生成,对胶质瘤的恶性演进起促进作用。 相似文献
8.
目的:探讨p14^ARF、MDM2和p53蛋白在脑胶质瘤组织中的表达及p14^ARF-MDM2-p53通路在胶质瘤进展中的意义。方法:应用免疫组化SP法检测25例Ⅱ级和23例Ⅳ级胶质瘤组织中-p14^ARF、MDM2和-p53蛋白的表达,并分析其与胶质瘤组织学分级之间的关系。结果:Ⅱ级和Ⅳ级胶质瘤中,MDM2蛋白的阳性表达率分别为24.00%(6/25)及56.52%(13/23)(P=0.021),p53蛋白的阳性表达率分别为28.00%(7/25)及60.87%(14/23)(P=0.022),二者阳性表达率均随胶质瘤恶性程度的增加而升高,Spearman等级相关分析显示,MDM2、p53的表达与胶质瘤分级呈正相关;p14^ARF的阳性表达率分别为76.00%(19/25)及34.78%(8/23)(P=0.004),其阳性表达率随胶质瘤恶性程度的增加而降低,Spearman等级相关分析显示,p14^ARF的表达与胶质瘤分级呈负相关(P〈0.05)。结论:脑胶质瘤组织中,MDM2和p53均呈不同程度的过度表达,且随恶性程度的增加表达水平增高;而p14^ARF随恶性程度的增加而表达水平降低。MDM2扩增、p53突变及p14^ARF蛋白低表达均与胶质瘤的进展有关。 相似文献
9.
目的:探讨促血管生成素-2(Ang-2)、CD105和CD34在脑胶质瘤中的表达及生物学意义。方法:应用免疫组化sP法检测45例胶质瘤和10例正常脑组织中Ang-2蛋白的表达及CDl05和CD34标记的MVD,并分析它们与胶质瘤临床病理因素的关系。结果:Ang-2在胶质瘤中的阳性表达率为62.2%,显著高于正常脑组织(P〈0.05)。胶质瘤组织中,CD105、CD34标记的MVD均明显高于正常脑组织。Ang-2表达的阳性标记指数及CD105标记的MVD与胶质瘤病理分级密切相关(P〈0.01),CD34标记的MVD与胶质瘤病理分级无明显相关(P〉0.05)。Ang-2与CD105、Ang-2与CD34均呈协同表达,CD105在胶质瘤中表达的特异性较CD34高。结论:Ang-2、CD105和CD34表达在促进胶质瘤的恶性演进中发挥重要作用;CD105较CD34更能准确反映肿瘤血管内皮细胞的增殖状态。 相似文献
10.
目的: beclin 1基因慢病毒表达载体稳定感染三阴性乳腺癌BT549细胞后,于短程低氧条件下探讨beclin 1基因对上皮间质转化( EMT)的影响。方法用带有pLenO-GTP Vector及pLenO-GTP-beclin 1 Vector的慢病毒以感染复数( MOI)为20分别感染BT549细胞,即实验对照组及实验组,未感染细胞作为空白对照。感染96 h后用倒置荧光显微镜观察荧光,估计感染效率;用Western blot法检测beclin 1基因是否在 BT549细胞中稳定表达;将各组细胞低氧培养12、24 h 后采用荧光定量 PCR、Western blot法及激光共聚焦显微镜检测EMT相关标志物;用Western blot法检测低氧培养24 h后的各组细胞Wnt/β-catenin信号通路的相关蛋白表达水平。用两样本t检验分析低氧时间对细胞EMT相关标志物的表达情况,余计量资料用方差分析进行统计。结果慢病毒感染BT549细胞96 h后,感染效率约为100%,实验组beclin 1蛋白高效稳定表达(F=107.200,P=0.000);低氧条件下,相对于空白对照组、实验对照组,实验组细胞的上皮标志物E-cadherin mRNA和蛋白表达水平上调(12 h:F=122.451、P=0.000,F=29.651、P=0.001;24 h:F=108.783、P=0.000,F=41.232、P=0.000),而间皮标志物 N-cadherin、vimentin及 fibronectin表达水平下调(12 h:N-cadherin F=92.918、P=0.000、F=138.034、P=0.000,vimentin F=135.313、P=0.000、F=39.765、P=0.000,fibronectin F=144.275、P=0.000;24 h:N-cadherin F=76.064、P=0.000、F=40.614、P=0.000, vimentin F=206.576、P=0.000、F=46.658、P=0.000,fibronectin F=411.405、P=0.000);相对于低氧培养12 h,各组细胞低氧培养24 h后E-cadherin表达水平下调(空白对照组:t=4.266、P=0.013,t=11.235、P=0.000;实验对照组:t=10.463、P=0.000,t=4.092、P=0.009;实验组:t=28.208、P=0.000,t=7.262、P=0.001),而 N-cadherin(实验组除外)、vimentin和fibronectin表达水平上调(空白对照组:N-cadherin t=3.072、P=0.037、t=7.146、P=0.002, vimentin t=6.384、P=0.003、t=7.476、P=0.002,fibronectin t=8.389、P=0.001;实验对照组:N-cadherin t=2.805、P=0.049、t=5.352、P=0.006,vimentin t=12.701、P=0.000、t=5.923、P=0.004,fibronectin t=7.318、P=0.002;实验组:N-cadherin t=7.849、P=0.001、t=1.987、P=0.184,vimentin t=11.097、P=0.000、t=13.626、P=0.000,fibronectin t=11.003、P=0.000);beclin 1基因与低氧环境对 BT549细胞E-cadherin、N-cadherin的表达水平有交互效应( E-cadherin: F=19.175、P=0.000,F=5.588、P=0.015;N-cadherin:F=8.238、P=0.006,F=5.934、P=0.016);低氧培养24 h后,实验组Wnt/β-catenin信号通路的β-catenin、Snail蛋白水平下调(β-catenin: F=18.169, P=0.003;Snail: F=11.098, P=0.010),而p-GSK-3β的蛋白水平上调(F=36.096, P=0.000)。结论 beclin 1基因在短程低氧条件下抑制BT549细胞EMT,而随时间的增加低氧促进 EMT;beclin 1基因在短程低氧环境下抑制 EMT 的机制可能与Wnt/β-catenin信号通路有关。 相似文献
11.
Shuichi Okubo Hai-Ning Zhen Nobuyuki Kawai Yoshihiro Nishiyama Reiji Haba Takashi Tamiya 《Journal of neuro-oncology》2010,99(2):217-225
l-Type amino acid transporter 1 (LAT1) is a neutral amino acid transport system and is a major route for the transport of large
neutral amino acids, including methionine, through the plasma membrane. LAT1 requires the heavy chain of 4F2 cell surface
antigen (4F2hc) for its functional expression. Positron emission tomography (PET) with l-[methyl-11C] methionine (MET) provides information about amino acid metabolism in brain tumors. We conducted a clinicopathologic study
to elucidate the correlation of LAT1 and 4F2hc expression with MET uptake in patients with newly diagnosed human gliomas.
Thirty-three newly diagnosed glioma patients were enrolled in this study. Uptake of MET in the tumor was evaluated with the
maximum standardized uptake value (SUVmax). Expression of the LAT1, 4F2hc, and CD34, and Ki-67 labeling index of the tumor
were analyzed by immunohistochemical staining, and the correlation with the SUVmax in the tumors was examined. Expression
of LAT1 and 4F2hc was higher in high-grade gliomas than in low-grade gliomas. The grade of LAT1 immunostaining increased with
glioma grade. LAT1 was mainly expressed in the tumor cytoplasm and vascular endothelium and 4F2hc was mainly expressed in
the tumor cytoplasm and plasma membrane. Expression of LAT1 but not 4F2hc was significantly correlated with MET SUVmax. Expression
of LAT1 in the tumor vascular endothelium is significantly correlated with CD34 positive microvessel density. In conclusion,
MET SUVmax correlates with LAT1 expression in the tumor in newly diagnosed gliomas. MET transport may be increased by an increased
number of microvessels combined with a higher density or activity of LAT1 in the tumor endothelial cells in high-grade gliomas.
Use of MET-PET as a molecular target combined with anti-angiogenesis in glioma therapy should be addressed in future studies. 相似文献
12.
Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models. 总被引:6,自引:0,他引:6
BACKGROUND AND OBJECTIVES: It has been said that amino acid transporters play an important role in supplying nutrition to cells and for cell proliferation. In this study, we examined whether LAT1 and 4F2hc are closely related to tumor growth. METHODS: Rat colon cancer cells (RCN-9) were injected into the spleen of 12 male rats (inbred F344/DuCrj). In each rat, liver samples including tumor lesions were immunostained with anti-LAT1 and anti-4F2hc antibodies. The staining area of LAT1 and 4F2hc tumor lesions was calculated by computer analysis. RESULTS: Sixty-eight tumor nodules were observed in 12 livers. Out of the 68 tumor nodules, 36 nodules (52.9%) indicated a positive staining of LAT1 and 32 (47.1%) had a negative staining of LAT1. However, the LAT1 expression was scarcely detected in non-tumor areas. In terms of the 4F2hc expression, there were 56 nodules (82.4%) with 4F2hc positive and 12 (17.6) with 4F2hc negative. In addition, the expression of 4F2hc in non-tumor areas was almost the same as the expression of 4F2hc in tumor lesions. The average tumor size of the group with LAT1 positive and 4F2hc positive (n = 31) was 0.845 +/- 0.232 mm(2), which was significantly larger than that of the group with LAT1 negative and 4F2hc negative group (n = 7) (0.090 +/- 0.028 mm(2)) or the group with LAT1 positive and 4F2hc negative (n = 5) (0.097 +/- 0.025 mm(2)), respectively (P = 0.0017, P = 0.007). CONCLUSION: LAT1 was related to tumor growth. We think that LAT1 can possibly enhance its ability to promote tumor growth in cooperation with 4F2hc. 相似文献
13.
14.
目的 本实验旨在研究骨肉瘤细胞中缺氧诱导因子-1α (hypoxia inducible factor-1α,HIF-1α)和环氧化酶-2 (cyclooxygenase 2,Cox-2)的表达及分析其与临床预后的相关性.方法 从我院自2003年1月至2009年1月就诊的骨肉瘤患者中筛选出18例,采集临床指标包括患者性别、年龄、发病部位、Enneking分期、组织病理学分型及术后随访患者生存情况.另选8例纤维结构不良患者作为阴性对照.采用免疫组化SP法进行肿瘤组织中HIF-1α和Cox-2表达的检测.结果 HIF-1α、Cox-2的表达均定位于细胞核内,呈棕黄(褐)色颗粒,在所有骨肉瘤患者均有表达,但表达的数量及着色强度有所差异,而纤维结构不良中无表达.单因素方差分析结果表明,HIF-1α的表达程度与患者性别(F=0.535,P=0.713)、年龄(F=0.311,P=0.865)、部位(F=1.211,P=0.353)无关,与患者的肿瘤分期(F=6.205,P=0.005)、转移灶有无(F=7.583,P=0.002)及病理类型(F=9.893,P=0.001)有关;Cox-2的表达程度与患者性别(F=1.102,P=0.381)、年龄(F=1.809,P=0.192)、部位(F=0.267,P=0.848)无关,与患者的肿瘤分期(F=7.583,P=0.003)和病理类型(F=4.721,P=0.018)及转移灶的存在与否(F=6.222,P=0.007)有关.相关分析结果表明,HIF-1α、Cox-2表达的相关系数为0.902 (P<0.001),有统计学意义.Log-rank单因素生存分析表明,HIF-1α表达(P=0.001)、Cox-2表达(P=0.006)、肿瘤分期(P=0.041)、病理学分类(P=0.025)及转移灶的存在与否(P=0.001)和骨肉瘤患者预后相关,而性别(P=0.774)、年龄(P=0.089)、发病部位(P=0.117)与患者预后无关.Cox回归模型结果提示HIF-1α、Cox-2是骨肉瘤预后相关的重要因素,且HIF-1α和Cox-2的高表达提示患者预后不良.结论 (1) HIF-1α及Cox-2在所有骨肉瘤患者均有表达,但表达的数量及着色强度有所差异.(2) HIF-1α及Cox-2在骨肉瘤中表达呈正相关.(3) HIF-1α及Cox-2在骨肉瘤中的表达与肿瘤分期,转移灶的有无及病理类型有关,且高表达与较差的预后相关. 相似文献
15.
L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors 总被引:5,自引:0,他引:5
Nawashiro H Otani N Shinomiya N Fukui S Ooigawa H Shima K Matsuo H Kanai Y Endou H 《International journal of cancer. Journal international du cancer》2006,119(3):484-492
L-type amino acid transporter 1 (LAT1) is a Na+-independent neutral amino acid transport agency and essential for the transport of large neutral amino acids. LAT1 has been identified as a light chain of the CD98 heterodimer from C6 glioma cells. LAT1 also corresponds to TA1, an oncofetal antigen that is expressed primarily in fetal tissues and cancer cells. We have investigated for the first time, the expression of the transporter in the human primary astrocytic tumor tissue from 60 patients. LAT1 is unique because it requires an additional single membrane spanning protein, the heavy chain of 4F2 cell surface antigen (4F2hc), for its functional expression. 4F2hc expression was also determined by immunohistochemistry. Kaplan-Meier analyses demonstrated that high LAT1 expression correlated with poor survival for the study group as a whole (p<0.0001) and for those with glioblastoma multiforme in particular (p=0.0001). Cox regression analyses demonstrated that LAT1 expression was one of significant predictors of outcome, independent of all other variables. On the basis of these findings, we also investigated the effect of the specific inhibitor to LAT1, 2-aminobicyclo-2 (2,2,1)-heptane-2-carboxylic acid (BCH), on the survival of C6 glioma cells in vitro and in vivo using a rat C6 glioma model. BCH inhibited the growth of C6 glioma cells in vitro and in vivo in a dose-dependent manner. Kaplan-Meier survival data of rats treated with BCH were significant. These findings suggest that LAT1 could be one of the molecular targets in glioma therapy. 相似文献
16.
背景与目的:人miR-10b编码基因位于染色体2q31HOXD8基因之间,有研究显示其特异性地高表达于多种肿瘤中,并与肿瘤的侵袭、迁移和远距离转移有关。本研究对不同级别胶质瘤组织及非肿瘤对照脑组织中miR-10b的表达水平进行检测和比较。方法:采用组织微阵列及锁定寡核苷酸原位杂交技术检测56例不同级别胶质瘤及10例非肿瘤对照脑组织中miR-10b的表达水平。结果:对照脑组织及WHOⅠ~Ⅱ级、Ⅲ级及Ⅳ级胶质瘤组织中miR-10b阳性标记指数(LI%)分别为36.87±20.63、18.86±14.04、12.13±11.56及4.93±6.45,4组间差异均有显著性(P<0.05~0.001),miR-10b LI%与肿瘤的良恶性分级呈显著负相关(rs=-0.61,P<0.001)。结论:miR-10b的表达水平与胶质瘤病理分级呈负相关。 相似文献
17.
目的:应用免疫组化法,检测COX-2、TRX-1在乳腺癌组织中表达,探讨COX-2、TRX-1表达与乳腺癌临床病理特征及预后因素的关系。方法:122例乳腺癌组织石蜡标本制作成乳腺癌组织芯片。免疫组化sP法检测COX-2、TRX-1表达。所有患者均接受规范性手术、术后辅助化疗及放疗,激素受体阳性病人接受5年的内分泌治疗。从手术日期到复发转移或随访截止日期(2008年7月)确定为患者无病生有溯。共有45例复发嘲多病例。结果:122例乳腺癌组织中COX-2、TRX-1均呈高表达,分别为58.2%、54.1%,且二者表达呈正相关(r=0.286,P=0.001);COX-2表达与临床分期(r=0.193,P=0.033)、肿块大小(r=0.192,P=0.034)及淋巴结转移(r=0.186,P=0.040)呈正相关,TRX-1表达与临床分期(r=0.206,P=0.023)、肿块大小(r=0.236,P=0.009)呈正相关,与淋巴结转移(r=0.175,P=0.054)不相关。COX-2或TRX-1表达与无病生存期呈负相关(P=0.027,P=0.046);COX-2和TRX-1共表达与无病生存期呈负相关(P=0.017)。结论:乳腺癌组织中COX-2、TRX-1均呈高表达,两者与乳腺癌患者预后密切相关;COX-2、TRX-1表达呈正相关,推测乳腺癌组织中TRX-1可能参与COX-2调节。 相似文献
18.
目的:探讨胰岛素样生长因子Ⅰ型受体(IGF-IR)在正常脑组织和脑胶质瘤中的分布和表达,及其与核增殖指标MIB-1的相关性。方法:应用免疫组织化学S-P法,对55例胶质瘤组织和10例正常脑组织中IGF-IR、MIB-1表达情况进行检测分析。结果:脑胶质瘤组织中IGF-IR阳性率明显高于正常脑组织(P〈0.05),并且随病理分级(WHO分级)的增高而增高,Ⅰ-Ⅱ级与Ⅲ-Ⅳ级的表达差异有显著性(P〈0.05);胶质瘤组织中IGF-IR的表达与MIB-1的表达密切相关(P〈0.01,rs=0.735)。结论:IGF-IR在脑胶质瘤的发生发展起重要作用,能促进肿瘤细胞的增殖,有可能成为临床病理诊断脑胶质瘤和判断预后的一个重要指标。 相似文献